News

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...
For younger acute myocardial infarction (AMI) survivors, living in marginalized neighborhoods is associated with adverse ...
The Medical City (TMC) has earned a spot in Newsweek and Statista’s 2025 list of top-performing hospitals across the Asia ...
Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.
Australia: A new study published in Circulation: Cardiovascular Imaging suggests that a novel automated score that ...
The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...
The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.
For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...
A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...
Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post ...
Treating coronary artery disease patients with monotherapy using clopidogrel or ticagrelor was associated with lower rates of ...
Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...